Cellosaurus logo
expasy logo

Cellosaurus HuH-28 (CVCL_2955)

[Text version]
Cell line name HuH-28
Synonyms HUH-28; HuH28; HUH28
Accession CVCL_2955
Resource Identification Initiative To cite this cell line use: HuH-28 (RRID:CVCL_2955)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Population: Japanese.
Doubling time: ~80 hours (PubMed=2852388); ~1 week (Note=Lot 09082006), ~88 hours (Note=Lot 01062011), 55-128 hours (Note=Lot 07222016), 5 days (Note=Lot 10022018) (JCRB=JCRB0426).
Omics: Deep exome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Liver; UBERON=UBERON_0002107.
Sequence variations
  • Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (DepMap=ACH-000808).
  • Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (DepMap=ACH-000808).
Genome ancestry Source: PubMed=30894373

Origin% genome
African3.05
Native American0
East Asian, North84.08
East Asian, South11.01
South Asian0
European, North0
European, South1.86
Disease Intrahepatic cholangiocarcinoma (NCIt: C35417)
Cholangiocarcinoma (ORDO: Orphanet_70567)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 37Y
Category Cancer cell line
STR profile Source(s): JCRB=JCRB0426; PubMed=25877200; RCB=RCB1943; TKG=TKG 0438

Markers:
AmelogeninX
CSF1PO9,12
D2S133819
D3S135815,16
D5S8189,12
D7S82010 (RCB=RCB1943)
10,11 (JCRB=JCRB0426; PubMed=25877200; TKG=TKG 0438)
D8S117911
D13S3179,12
D16S5399
D18S5115
D19S43313,14.2
D21S1130,33.2
FGA23
Penta D9,10
Penta E13,22
TH019
TPOX8
vWA17

Run an STR similarity search on this cell line
Publications

PubMed=2852388; DOI=10.1007/BF01851205
Kusaka Y., Tokiwa T., Sato J.
Establishment and characterization of a cell line from a human cholangiocellular carcinoma.
Res. Exp. Med. (Berl.) 188:367-375(1988)

PubMed=2856443
Kusaka Y., Muraoka A., Tokiwa T., Sato J.
Establishment and characterization of a human cholangiocellular carcinoma cell line.
Hum. Cell 1:92-94(1988)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=21451941; DOI=10.1007/s00534-011-0376-7
Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y., Tsuchiya T., Gotoh M.
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
J. Hepatobiliary Pancreat. Sci. 18:700-711(2011)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

CLPUB00275
Zach S., Birgin E., Ruckert F.
Primary cholangiocellular carcinoma cell lines.
J. Stem Cell Res. Transplant. 2:1013-1013(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26956050; DOI=10.18632/oncotarget.7914; PMCID=PMC4991440
Ding X.-W., Chaiteerakij R., Moser C.D., Shaleh H.M., Boakye J., Chen G., Ndzengue A., Li Y., Zhou Y.-L., Huang S.-B., Sinicrope F.A., Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Oncotarget 7:20080-20092(2016)

PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., El-Bardeesy N.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31077409; DOI=10.1002/hep.30704
Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.
Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.
Hepatology 70:1614-1630(2019)

Cross-references
Cell line collections (Providers) JCRB; JCRB0426
RCB; RCB1943
TKG; TKG 0438
Cell line databases/resources CLO; CLO_0050855
cancercelllines; CVCL_2955
Cell_Model_Passport; SIDM01735
DepMap; ACH-000808
Biological sample resources BioSample; SAMN03470952
BioSample; SAMN03472037
BioSample; SAMN10987843
Chemistry resources ChEMBL-Cells; CHEMBL3308110
PharmacoDB; HuH28_638_2019
Encyclopedic resources Wikidata; Q54896845
Gene expression databases ArrayExpress; E-MTAB-783
GEO; GSM887147
GEO; GSM888219
Polymorphism and mutation databases Cosmic; 924163
Cosmic; 1373551
Cosmic; 2674045
IARC_TP53; 28291
Progenetix; CVCL_2955
Entry history
Entry creation04-Apr-2012
Last entry update02-May-2024
Version number31